RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

Exclusion Criteria

• •1. Participants are unable to undergo (even partially) any of the imaging procedures;
• •2. Participants with a known history of cardiac disease including:
• •1. myocardial infarction, previous coronary revascularization, or chronic ischemic cardiomyopathy
• •2. primary myocardial disease such as cardiac amyloidosis or hypertrophic cardiomyopathy
• •3. known left ventricular dysfunction
• •4. moderate or severe aortic or mitral stenosis or regurgitation
• •3. Participants in whom adenosine stress testing is contraindicated, including but not limited to:
• •1. Participants with severe COPD or chronic asthma.
• •2. Participants with second- or third-degree atrioventricular block without a pacemaker.
• •4. Participants with claustrophobia to an extent that would limit their ability to undergo SPECT and PET imaging (patients whose claustrophobia is known to be readily controlled with drugs or psychological support may be enrolled).
• •5. Participants who are on sildenafil (Viagra) or oral dipyridamole (Persantine, Aggrenox) therapy or on any PDE5 inhibitor (i.e. tadalafil, avanafil, vardenafil),and for whom its use cannot be terminated or suspended for ≥24 hours prior to treatment of study drug.
• •6. Participants with significant co-morbidities that would prevent appropriate completion of the protocol procedures.
• •7. Participants who have participated in another research study using investigational drugs within the 30 days prior to enrollment or through the duration of the trial (patients in observational studies with approved agents and participants known to be on placebo may be enrolled).
• •8. Participants who have previously participated in this study.
• •9. Subjects scheduled for, or planning to undergo, any interventional cardiac procedures between enrollment and ICA (pathway 1) or signing of informed consent and 15O-H2O PET MPI (pathway 2 and 3)